Favco delivered a plendid performance on its back of orders. 10.38 cents may push its PE to as low as 3-4 times. Strong NTAB and its branding on cane. We will buy more Favco. POS and Bonia having slight increase in performance and the later with reduce profit. We recommend still a hold. Vice versa, we start not comfortable to Bernas as revenue slightly reduce. That may indicate not much room to growth for its business and profit is decreasing for some quarters. We may dispose and change to other company. An increased revenue but again registered another quarter of loss for Lay Hong. We will look for another quarter before we decide whether is cost increase or failure of management to control cost.
EPS of 7.38 cents via improved revenue and profit. We will start to invest a little more into this company. It has given a good growth pattern and we also like it dividend policy.
We believe the coming week will see technical rebound but we do not expect is a strong one. Both HSBC PMI and German Lfo show good sign but is still too early. We will think it will be a mild rebound with range bound weakness expected. Our first support is 1580 – 1600.
We are glad that our portfolio of stocks are performed better than average and KLCI in term of their EPS. Beside of FocusP profit decreased, most others are doing well. We maintain hold and profit from their dividend as of now.
We recommend a buy below RM 8.00 now. As its continuous splendid results plus a strong NTAV at RM 11.390. The current quarter EPS pushes its PE as low as 5-6 times. With its branding, market segment and growth potential. We should see Allianz excel at RM 15.00 in 12 months time. We recommend buy on any weakness.
Even with a PE of 20 times now and NTAV of RM 1.57. Due to its RHB Cap corporate exercise. We still value OSK at RM 2.00 and continue recommending a hold or buy if dip below RM 1.40. Unless unforseen and it should have good return within 6 months time.
3rd quarter results indicated 10% improved revenue and net profit almost doubled. For its industry, a PE of 12-15 times are fair to the market. 3 quarters earnings push potential PE back to 10. Thus, we upgrade its new value to RM 12.00
We like new Camry launching and the recovery of oil and gas industry. Especially its oil and gas arm pending listing. We recommended a hold or buy when dip as long term hold.
Yield has increased as the price at RM 1.320. We will buy more if price drop below our comfort zone between RM 1.200 to RM 1.300
We started our mild bargain hunting mildly. Also, we continue to nibbling AUD at RM 3.18. We will slowly buy more when market adjust lower.
Stemlfe registered est. 15% increase in revenue but 1.84 cents EPS. Which over RM 2 mil. from other income. We dont consider other income as performance as it may means many things. Taking out other income we see a slight increase in cost as well. Therefore probably only 5% increase in profit. We think is ok but we think there is a need for Stemlfe to look into other new innovative health science. Stem cell is good but with new biz is definitely always a good biz model R&D for new channels of income.